European Patent Office Upholds Introgen Patent
Earlier this year, Schering-Plough filed an opposition against the issuance of the European patent directed to "combination therapy with p53 and conventional chemotherapy and/or radiation."
This is the third successful outcome over a period of three years in oppositions involving Schering-Plough, Introgen said in a statement.
The patent, exclusively licensed to Introgen from The Board of Regents of The University of Texas System, covers...
To view the full article, register now.